General Principles of Pharmacology and Toxicology

Similar documents
General Principles of Pharmacology and Toxicology

PHA5128 Dose Optimization II Case Study I Spring 2013

BASIC PHARMACOKINETICS

CLINICAL PHARMACOKINETICS INDEPENDENT LEARNING MODULE

PHA Second Exam Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

PHA Second Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

Renal Function. 1. Glomerular filtration 2. Active tubular secretion 3. Passive tubular reabsorption 4. Excretion

PHA Final Exam Fall 2006

Basic Concepts of TDM

PHA 5127 FINAL EXAM FALL On my honor, I have neither given nor received unauthorized aid in doing this assignment.

Renal Clearance. Dr. Eman El Eter

PHA First Exam Fall 2003

PHA Final Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

TDM. Measurement techniques used to determine cyclosporine level include:

PHA Second Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

1. If the MTC is 100 ng/ml and the MEC is 0.12 ng/ml, which of the following dosing regimen(s) are in the therapeutic window?

Renal Impairment From Dettli to Guideline: What can we learn?

Drug elimination and Hepatic clearance Chapter 6

Basic Concepts in Pharmacokinetics. Leon Aarons Manchester Pharmacy School University of Manchester

PHA First Exam. Fall 2004

LD = (Vd x Cp)/F (Vd x Cp)/F MD = (Css x CL x T)/F DR = (Css x (Vm-DR))/Km Css = (F x D)/(CL x T) (Km x DR)/(Vm DR)

Nonlinear Pharmacokinetics

Basic Pharmacokinetics and Pharmacodynamics: An Integrated Textbook with Computer Simulations

BIOL 2402 Renal Function

PHA 5128 Final Exam Spring 2004 Version A. On my honor, I have neither given nor received unauthorized aid in doing this assignment.

Rational Dose Prediction. Pharmacology. φαρμακον. What does this mean? pharmakon. Medicine Poison Magic Spell

TDM. Generally, hepatic clearance is determined by three main factors: These three factors can be employed in the following equation:

PHA Final Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

Biomath M263 Clinical Pharmacology

Drug Dosing in Renal Insufficiency. Coralie Therese D. Dimacali, MD College of Medicine University of the Philippines Manila

Renal Physiology. April, J. Mohan, PhD. Lecturer, Physiology Unit, Faculty of Medical Sciences, U.W.I., St Augustine.

You should know the T max for any substance that you use and for PAH ; T max = mg / min

RENAL SYSTEM 2 TRANSPORT PROPERTIES OF NEPHRON SEGMENTS Emma Jakoi, Ph.D.

Lippincott Questions Pharmacology

One-Compartment Open Model: Intravenous Bolus Administration:

PHA Second Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

Pharmacokinetics of Drugs. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia

PHA Spring First Exam. 8 Aminoglycosides (5 points)

Understand the physiological determinants of extent and rate of absorption

Estimation of Serum Creatinine, Urine Creatinine and Creatinine Clearance. BCH472 [Practical] 1

Chapter-V Drug use in renal and hepatic disorders. BY Prof. C.Ramasamy, Head, Dept of Pharmacy Practice SRM College of Pharmacy, SRM University

Nontraditional PharmD Program PRDO 7700 Pharmacokinetics Review Self-Assessment

Mechanisms of Drug Action

PHAR 7632 Chapter 16

DRUG ELIMINATION II BILIARY EXCRETION MAMMARY, SALIVARY AND PULMONARY EXCRETION

Name: UFID: PHA Exam 2. Spring 2013

ADME Review. Dr. Joe Ritter Associate Professor of Pharmacology

Pharmacokinetics Overview

TDM Lecture 7 5 th Stage. TDM of Digoxin. Uses: Digoxin is usually used in heart failure associated and atrial fibrillation.

Biopharmaceutics. Tips Worth Tweeting. Contributor: Sandra Earle

Pharmacogenetics and Pharmacokinetics

PHA 5128 Spring 2009 First Exam (Version B)

Multiple IV Bolus Dose Administration

A novel microdose approach to assess bioavailability, intestinal absorption, gut metabolism, and hepatic clearance of simeprevir in healthy volunteers

PHA5128 Dose Optimization II Case Study 3 Spring 2013

BIOPHARMACEUTICS and CLINICAL PHARMACY

General Principles of Pharmacology and Toxicology

Regulation of fluid and electrolytes balance

Introduction to Pharmacokinetics (PK) Anson K. Abraham, Ph.D. Associate Principal Scientist, PPDM- QP2 Merck & Co. Inc., West Point, PA 5- June- 2017

Clearance and Reabsorption. Use the following data to answer these questions. a. plasma flow rate in the afferent arterioles:

The kidney. (Pseudo) Practical questions. The kidneys are all about keeping the body s homeostasis. for questions Ella

Click to edit Master title style

Functional morphology of kidneys Clearance

Winston Spencer Liauw Cancer Care Centre, St George Hospital, Gray Street, Kogarah NSW 2217, Australia

BCH472 [Practical] 1

Lecture-2 Review of the previous lecture:

Renal Blood flow; Renal Clearance. Dr Sitelbanat

Metformin Associated Lactic Acidosis. Jun-Ki Park 9/6/11

Principles of Toxicokinetics/Toxicodynanics

We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors

PHA 5128 CASE STUDY 5 (Digoxin, Cyclosporine, and Methotrexate) Spring 2007

Filtration and Reabsorption Amount Filter/d

PHA 5128 Spring 2000 Final Exam

Based on the information in the official labeling, please answer the following:

Excretion of Drugs. Prof. Hanan Hagar Pharmacology Unit Medical College

Pharmacokinetic parameters: Halflife

Basic Pharmacokinetic Principles Stephen P. Roush, Pharm.D. Clinical Coordinator, Department of Pharmacy

Glomerular Filtration Rate. Hui Li, PhD, FCACB, DABCC

Evaluation and Quantitative Prediction of Renal Transporter-Mediated Drug-Drug Interactions. Bo Feng, Ph.D. DDI 2017 June 19-21, 2017

Excretion Chapter 29. The Mammalian Excretory System consists of. The Kidney. The Nephron: the basic unit of the kidney.

Adjusting phenytoin dosage in complex patients: how to win friends and influence patient outcomes

** Accordingly GFR can be estimated by using one urine sample and do creatinine testing.

Pharmacokinetics in Drug Development. Edward P. Acosta, PharmD Professor & Director Division of Clinical Pharmacology Director, CCC PK/PD Core

Pressure Diuresis 9 Sample Student Essays

Principal Investigator: Marion, Alan, S, M.D., MDS Pharma Services (US) Inc., 621 Rose Street, PO Box 80837, Lincoln, NE 68502, USA

Prediction of the Effects of Renal Impairment on the Clearance for Organic Cation Drugs that. undergo Renal Secretion: A Simulation-Based Study

NOTE FOR GUIDANCE ON TOXICOKINETICS: THE ASSESSMENT OF SYSTEMIC EXPOSURE IN TOXICITY STUDIES S3A

(KFTs) IACLD CME, Monday, February 20, Mohammad Reza Bakhtiari, DCLS, PhD

Chapter 23. Composition and Properties of Urine

PHA 5128 Case Study 4 (Answers) Total Cp = Unbound Cp/fu.

Pharmacokinetics of strong opioids. Susan Addie Specialist palliative care pharmacist

Pharmacokinetic Calculations

Pharmacokinetics of Rifampicin in African Children Evaluation of the new WHO dosing guidelines

Physiology questions review

Section 5.2: Pharmacokinetic properties

= (6000 ml air / min * 0.04 ml CO 2 / ml air) / 54 ml CO 2 / dl plasma

PHA 4120 Second Exam Key Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

PROBLEM SET 7.1 FLUID VOLUMES, GLOMERULAR FILTRATION AND CLEARANCE

DMPK. APRIL 27 TH 2017 Jan Neelissen Scientific Adviser Science & Technology

Transcription:

General Principles of Pharmacology and Toxicology Parisa Gazerani, Pharm D, PhD Assistant Professor Center for Sensory-Motor Interaction (SMI) Department of Health Science and Technology Aalborg University

2 Definitions and units symbols Symbol Units Definition A mg Amount of drug in body AUC mg*hour/l Total area under the plasma drug concentration-time curve AUC 0- mg*hour/l area under the plasma drug concentration-time curve from zero to infinite time AUC iv mg*hour/l area under the plasma drug concentration-time curve after an IV dose AUC oral mg*hour/l area under the plasma drug concentration-time curve after an oral dose C mg/ml Concentration of drug in plasma C 0 mg/ml Concentration of drug in plasma after a single dose extrapolated back to zero time C b mg/ml Concentration of drug in blood CL Total clearance of drug from plasma CL CR Creatinine clearance

3 Symbol Units Definition CL GF CL H Renal drug clearance by glumerular filtration Hepatic clearnce of drug from plasma CL int CL R Intrinsic clearance of drug in an organ of elimination Renal clearance of drug CL S Renal drug clearance by tubular secretion C max mg/l Maximum plasma drug concentration during a dosing interval C min mg/l Minimum plasma drug concentration during a dosing interval C ss mg/l Concentration of drug in plasma at steady state during a constant-rate intravenous infusion C uss mg/l Unbound concentration of drug in plasma at steady state during a constant-rate intravenous infusion C u mg/l Unbound drug concentration in plasma

4 Symbol Units Definition DR mg/hour Dosing rate E ratio Extraction ratio for an organ E H ratio Hepatic extraction ratio EC 50 mg/l Concentration giving one-half the maximum effect E max varies Maximum effect DR mg/hour Dosing rate E ratio Extraction ratio for an organ E H ratio Hepatic extraction ratio EC 50 mg/l Concentration giving one-half the maximum effect E max varies Maximum effect

5 Symbol Units Definition F ratio Bioavailability of drug f e ratio Fraction of drug systematically available that is excreted unchanged in urine f g ratio Fraction of an oral dosethat is absorbed intact into the portal circulation f H ratio Fraction of drug entering the liver that escapes extraction f m ratio Fraction of drug systematically available that is converted to a metabolite FR ratio Fraction of drug reaching the renal tubular fluid that is reabsorbed f u ratio Fraction of drug unbound in plasma f ut ratio Fraction of drug unbound in plasma GFR Glomerular filtration rate k /hour Elimination rate constant

6 Symbol Units Definition k a mm Association constant for the binding of drug to protein k m mg/l Michaelis-Menten constant Λ (lambda) ratio Ratio of concentrationof drug in whole blood to that in plasma P u mm Concentration of drug that does not bind drug Q H Hepatic blood flow (portal vein plus hepatic artery) V L Volume of distribution v mg/hour Velocity of enzyme reaction (conversion of drug to metabolite) V max mg/hour Maximal rate of enzyme reaction of saturating substrate concentration V p L Plasma volume V T L Physiologic volume outside plasma into which drug distributes Τ (tau) hour Dosing interval

7 Equations Elimination rate: CLxC Elimination rate = clearance (CL)xplasma drug concentration(c) mg/hour mg/l DR = CLxC ss Maintenance dose rate (DR) = clearance (CL)xsteady state drug concentration (C ss ) mg/hour mg/l C b = Cxλ and then λ = C b/ C Plasma concentration ratio = drug concentration in whole blood drug concentration in plasma

8 V = A/C Volume of distribution = total amount of drug in the body /plasma drug concentration V = V p + f u /f ut x V T Volume of distribution = plasma volume + fraction unbound in plasma fraction unbound in tissue x tissue volume Loading dose = V x C Loading dose = volume of distribution x target plasma concentration C t = C 0 x e kt Concentration at various time after the dose = Concentration at time zero x e kt K is elimination rate constant and t is time.

9 T 1/2 = 0.693/k Half-life (a reciprocal function of elimination rate constant). 0.693 is the natural logarithm of 2. 0.693xV T 1/2 =, K = CL/V CL CL H = Q H xe H Hepatic clearance = hepatic blood flow x hepatic extraction ratio E H = f u xcl int Q H + f u x CL int Unbound fraction x intrinsic clearance Extraction ratio = Blood flow + Unbound fraction x intrinsic clearance

10 CL int = V max /K m V max is the maximal velocity of the reaction at saturating substrate concentration or the maximal rate at which the enzyme can convert the drug to a metabolite. Km is the Michaelis constant and expresses how tightly the enzyme binds the drug substrate, the lower the Km, the tighter the binding! C LH = QH x f u xcl int Q H + f u x CL int F = f g x f H Bioavailability = fraction absorbed x fraction escaping first pass clearance F = AUC oral / AUC iv f H= 1 E H (the max oral bioavailability if the drug was totally absorbed from the gut into the portal circulation, fg = 1)

11 CL = CL R + CL H Total clearance = renal clearance + hepatic clearance f e = CL R /CL Fraction excreted unchanged = renal clearance/total clearance CL R = f u (GFR + CLs) (1- FR) Rnal clearance is the sum of glomerular filtration clearance (f u xgfr) and secretion clearance (f u x CL s ) multiplied by the fraction of drug that escapes reabsoption from the renal tubule (1- FR). F u = C u /C Fraction unbound = unbound drug concentration/total drug concentration Css = (FxDR)/CL Css is the steady state blood concentration and is a function of the dose rate, the bioavailability and the clearance of the drug.

12 CL () = dose (mg) AUC 0- (mgxhour/l) The AUC from zero time to the last plasma sample is determined as a number of trapezoids, and the area from the last data point (C last ) to infinite time is calculated as C last /k, where k is the elimination rate constant of the lowest elimination phase. V (L) = CL = t 1/2 (hour) xcl () 0.693 F xdose (mg) AUC 0-